• Tianjin Pharmaceutical Da Ren Tang plans an annual distribution agreement with Taiping Medicine, TJZX Medicine, running to Dec. 31, 2026.
• Caps product supply at RMB 113 million including tax; minimum guaranteed sales set at RMB 67.8 million including tax.
• Targets a pilot shift to a distributor-led marketing model in Tianjin to cut costs, tighten compliance, protect market share.
• Pricing uses an invoice-discount mechanism; maximum discount rate set at 22% versus a prior 25% benchmark.
• Deal classified as an interested-person transaction; value equals 1.61% of net tangible assets, below shareholder-approval thresholds.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tianjin Pharmaceutical Da Ren Tang Group Corporation Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: 20Q3Y58344OTOEEN) on August 07, 2026, and is solely responsible for the information contained therein.